A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability

References

• US Food and Drug Administration. Prograf Drug Approval Package. Silver Spring, MA, USA. 1994. http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050708_prograf_toc.cfm. Accessed June 4, 2013
   Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623–53
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Advagraf European Public Assessment Report Annex I: Summary of Product Characteristics. London, UK. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000712/WC500022234.pdf. Accessed June 4, 2013
   Google Scholar
• Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920–6
   PubMed Web of Science ®Google Scholar
• Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009;31:436–42
   PubMed Web of Science ®Google Scholar
• taatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001;16:1905–9
   Google Scholar
• Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003;63:1247–97
   PubMed Web of Science ®Google Scholar
• Ekberg H, van Gelder T, Kaplan B, et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation 2011;92:82–7
   PubMed Web of Science ®Google Scholar
• Kahan BD, Welsh M, Urbauer DL, et al. Low intraindividual variability of cyclosporine A exposure reduces chronic rejection incidence and health care cost. J Am Soc Nephrol 2000;11:1122–31
   PubMedGoogle Scholar
• European Medicines Agency. Advagraf European Public Assessment Report: Scientific Discussion. London, UK. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000712/WC500022237.pdf. Accessed June 5, 2013
   Google Scholar
• Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation 2011;92:648–52
   PubMed Web of Science ®Google Scholar
• Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005;37:1211–3
   PubMed Web of Science ®Google Scholar
• Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010;25:2757–63
   PubMed Web of Science ®Google Scholar
• Pollock-Barziv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant 2010;14:968–75
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Immunosuppressive therapy for renal transplantation in adults. Technical Appraisal 85. London, UK. 2004. http://www.nice.org.uk/TA85. Accessed 3 March, 2014
   Google Scholar
• Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009;9:2505–13
   PubMed Web of Science ®Google Scholar
• Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005;37:867–70
   PubMed Web of Science ®Google Scholar
• NHS Blood and Transplant. Transplant Activity in the UK. Activity report 2011–12. Watford, UK. 2012. http://www.organdonation.nhs.uk/statistics/transplant_activity_report/current_activity_reports/ukt/activity_report_2011_12.pdf. Accessed June 4, 2013
   Google Scholar
• McEwan P, Dixon S, Baboolal K, et al. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. Pharmacoeconomics 2006;24:67–79
   PubMed Web of Science ®Google Scholar
• Krämer BK, and the Tacrolimus Prolonged Release Renal Study Group. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplan 2010;10:2632–43
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Peritoneal dialysis in the treatment of stage 5 chronic kidney disease. London, UK. 2012. http://guidance.nice.org.uk/CG125/NICEGuidance/pdf/English. Accessed June 4, 2013
   Google Scholar
• The Renal Association. RA Guidelines – Haemodialysis. Petersfield, UK. 2009. http://www.renal.org/clinical/guidelinessection/haemodialysis.aspx. Accessed June 4, 2013
   Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices–budget impact analysis. Value Health 2007;10:336–47
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London, UK. 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed June 4, 2013
   Google Scholar
• Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011;14:357–66
   PubMedGoogle Scholar
• Ro H, Min SI, Yang J, et al. Impact of tacrolimusintraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit 2012;34:680–5
   PubMed Web of Science ®Google Scholar
• Guirado L, and the GREAT Study Group. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant 2011;11:1965–71
   PubMed Web of Science ®Google Scholar